Navigation Links
Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
Date:10/25/2007

LOD, Israel, October 25 /PRNewswire/ -- Glycominds Ltd., a bio-diagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today entering into a research agreement with Fox Chase Cancer Center (FCCC), an NCI designated cancer center to develop a new diagnostics blood test for breast cancer.

"We are very pleased to work with FCCC on this project," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP R&D. "Glycominds' anti-glycan antibodies biomarkers approach together with the FCCC excellent patient records, samples and clinical know-how give this project a high basis for success."

"Glycominds' glycan biomarker technology stands out as innovative and unique. We hope that just as Glycominds was able to successfully develop new diagnostic and prognostic biomarkers for Autoimmune disorders, we will be able to identify glycans that can be useful in the early detection of cancer," stated Dr. Andrew K. Godwin, FCCC's Director of the Clinical Molecular Genetics Laboratory and the Biosample Repository . "I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer and improve the health and quality of life for millions of women."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers. http://www.glycominds.com

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: +1-646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: +1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Purchase of Madison broadband network may bring improved service
2. Wisconsin fares slightly better in venture capital chase
3. Metavante completes purchase of check processing firm
4. Logicalis purchases Solution Technology for $90M
5. Merge eFilm announces stock repurchase plan
6. Wisconsin based Graphics Distribution, Inc. purchased by Florida company
7. GE Medicals Acquisitions May Prompt More Purchases
8. Green Bay Software Company Purchased by GE
9. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
10. Cancer siRNA Oligo Set Version 1.0
11. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. ... pluripotent stem cell-derived islet replacement therapy for the treatment ... at ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global ... 25th at Moscone West in San Francisco.  ... the presentations are as follows:Event: , Focus Session: Tools ...
(Date:6/22/2016)... and ALBANY, N.Y. , ... (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: ... licensed Teewinot,s technology to produce and sell the ... The CBCA analytical standard is manufactured using Teewinot,s ... expression of cannabinoid biosynthetic genes in microorganisms for ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):